Furthermore, since MEK inhibition sensitizes MLL-rearranged ALL cells to prednisolone regardless of the RAS mutations status, RAS-wildtype MLL-rearranged infant ALL patients may also benefit from MEK inhibitor treatment through enhanced sensitivity to prednisolone. The gene discussed is MAP2K7; the disease is acute lymphoblastic leukemia.